Table 1.
Basic demographics and medical information
| Total | IPF | CTD-ILD | Non-IPF/non-CTD | |
|---|---|---|---|---|
| n = 90 | n = 27 (30%) | n = 34 (37.8%) | n = 29 (32.2%) | |
| Femalea,b | 53 (58.9%) | 8 (29.6%) | 24 (70.6%) | 21 (72.4%) |
| Agea,c (years) | 66.5 (18) | 71.0 (12) | 56.0 (16) | 68.0 (15) |
| Ethnicity | ||||
| Caucasian | 76 (84.4%) | 25 (92.6%) | 25 (73.5%) | 26 (89.7%) |
| Other | 14 (15.6%) | 2 (7.4%) | 9 (26.5%) | 3 (10.3%) |
| Smoking Statusa,b | ||||
| Never smoked | 44 (48.9%) | 5 (18.5%) | 19 (55.9%) | 20 (69.0%) |
| Ever smoked | 46 (51.1%) | 22 (81.4%) | 15 (454.1%) | 9 (31.0%) |
| Treatments | ||||
| Cortico-steroidsa,b | 43 (47.8%) | 2 (7.4%) | 22 (64.7%) | 19 (65.5%) |
| Anti-fibrotic agentsa,b | 26 (28.9%) | 24 (88.9%) | 1 (2.9%) | 1 (3.4%) |
| Immunosuppressiona,b,c | 35 (38.9%) | 0 | 25 (73.5%) | 10 (34.5%) |
| Anti-reflux therapy | 30 (33.3%) | 9 (33.3%) | 12 (35.3%) | 9 (31.0%) |
| Supplemental oxygen | ||||
| Continuous | 11 (12.2%) | 5 (18.5%) | 3 (8.8%) | 3 (10.3%) |
| Pulmonary hypertension | ||||
| Present | 12 (13.3%) | 2 (7.4%) | 5 (14.7%) | 5 (17.2%) |
| Lung function | ||||
| FVC %Predicted n = 90 | 74 (31) | 77 (45) | 74 (32) | 56 (47) |
| DLCO %Predicted n = 88 | 51 (26) | 47.5 (23) | 49 (46) | 51 (33) |
| TLC %Predicted n = 40 | 66 (27) | 63 (39) | 67 (27) | 66 (29) |
All data shown as number (percent) or median (interquartile range)
IPF idiopathic pulmonary fibrosis, CTD-ILD connective-tissue disease associated interstitial lung disease, FVC forced vital capacity, DLCO diffusing capacity of the lungs for carbon monoxide, TLC total lung capacity
aSignificant difference between IPF and CTD-ILD
bSignificant difference between IPF and other
cSignificant difference between CTD-ILD and non-IPF/non-CTD